Altre lingue Daxor Corporation Nyse

Azioni

DXR

US2394671034

Mercato chiuso - Nyse Altri mercati azionari 22:30:01 03/05/2024			Variaz. 5gg	Var. 1 gen.
9,8 ^USD	-0,81%		+1,55%	+2,08%

16/04	Daxor Corporation annuncia due nuovi studi che convalidano i benefici clinici della diagnostica del volume ematico (BVA-100TM) di Daxor nei pazienti con insufficienza cardiaca ambulatoriale per la misurazione della congestione	CI
10/04	Daxor Corporation annuncia un nuovo account ospedaliero presso un importante ospedale di Chicago	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion	16/04
Daxor Corporation Announces Two New Studies Validating the Clinical Benefits of Daxor?s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion	16/04
Daxor Corporation to Exhibit at the Medaxiom Cardiovascular Transforum Conference Spring'24 to Advance Awareness and Further Adoption of Daxor's Blood Volume Diagnostic	16/04
DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING’24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100™)	15/04
Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital	10/04
Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital	10/04
Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24	01/04
Daxor to Acquire Volumex, Megatope to Increase Diagnostics Suite	25/03
Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics	25/03
Daxor Corporation has entered into a definitive agreement to acquire Volumex®, Megatope® and Glofil® from Iso-Tex Diagnostics, Inc.	25/03
Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024	22/03
Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023	18/03
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders	18/03
Daxor Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	15/03
Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base	11/03
Daxor Corporation Announces Sales to Three New Hospitals Furthering Expansion of Its User Base	11/03
Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor’s Unique Clinical Utility for Heart Failure Patients	08/03
Daxor Corporation Announces New Data from Duke University Medical Center Validating the Benefits of Blood Volume Analysis	08/03
Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference	26/02
Daxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer Acquisitions	12/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Daxor Corporation Nyse

Azioni

DXR

US2394671034

Altre lingue

Filtri